Loading...

Eckert & Ziegler BEBIG

ENXTBR:EZBG
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EZBG
ENXTBR
€38M
Market Cap
  1. Home
  2. BE
  3. Healthcare
Company description

Eckert & Ziegler BEBIG S.A., through its subsidiaries, develops, manufactures, and sells radiation equipment and related products based on isotope technology. The last earnings update was 210 days ago. More info.


Add to Portfolio Compare Print
  • Eckert & Ziegler BEBIG has significant price volatility in the past 3 months.
EZBG Share Price and Events
7 Day Returns
0%
ENXTBR:EZBG
-0.4%
Europe Medical Equipment
-1.6%
BE Market
1 Year Returns
81.1%
ENXTBR:EZBG
10.4%
Europe Medical Equipment
-16.7%
BE Market
EZBG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Eckert & Ziegler BEBIG (EZBG) 0% -4.1% 48.2% 81.1% 117.3% -27.6%
Europe Medical Equipment -0.4% 3.8% 6.6% 10.4% 45.8% 69.3%
BE Market -1.6% 1.3% 0.1% -16.7% -15.2% 2.5%
1 Year Return vs Industry and Market
  • EZBG outperformed the Medical Equipment industry which returned 10.4% over the past year.
  • EZBG outperformed the Market in Belgium which returned -16.7% over the past year.
Price Volatility
EZBG
Industry
5yr Volatility vs Market
Related Companies

EZBG Value

 Is Eckert & Ziegler BEBIG undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Eckert & Ziegler BEBIG to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Eckert & Ziegler BEBIG.

ENXTBR:EZBG Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year BE Government Bond Rate 0.8%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTBR:EZBG
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year BE Govt Bond Rate 0.8%
Equity Risk Premium S&P Global 9.2%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.668 (1 + (1- 29%) (2.42%))
0.68
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.77% + (0.8 * 9.23%)
8.15%

Discounted Cash Flow Calculation for ENXTBR:EZBG using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Eckert & Ziegler BEBIG is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTBR:EZBG DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 2.20 2.13 2.07 2.01 1.95
Source Est @ -2.95% Est @ -2.95% Est @ -2.95% Est @ -2.95% Est @ -2.95%
Present Value
Discounted (@ 8.15%)
2.03 1.82 1.64 1.47 1.32
Present value of next 5 years cash flows €8.28
ENXTBR:EZBG DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €1.95 × (1 + 0.77%) ÷ (8.15% – 0.77%)
€26.60
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €26.60 ÷ (1 + 8.15%)5
€17.98
ENXTBR:EZBG Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €8.28 + €17.98
€26.25
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €26.25 / 2.33
€11.26
ENXTBR:EZBG Discount to Share Price
Calculation Result
Value per share (EUR) From above. €11.26
Current discount Discount to share price of €16.30
= -1 x (€16.30 - €11.26) / €11.26
-44.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Eckert & Ziegler BEBIG is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Eckert & Ziegler BEBIG's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Eckert & Ziegler BEBIG's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTBR:EZBG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €0.27
ENXTBR:EZBG Share Price ** ENXTBR (2019-02-18) in EUR €16.3
Europe Medical Equipment Industry PE Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 28.85x
Belgium Market PE Ratio Median Figure of 93 Publicly-Listed Companies 14.64x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Eckert & Ziegler BEBIG.

ENXTBR:EZBG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:EZBG Share Price ÷ EPS (both in EUR)

= 16.3 ÷ 0.27

61.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eckert & Ziegler BEBIG is overvalued based on earnings compared to the Europe Medical Equipment industry average.
  • Eckert & Ziegler BEBIG is overvalued based on earnings compared to the Belgium market.
Price based on expected Growth
Does Eckert & Ziegler BEBIG's expected growth come at a high price?
Raw Data
ENXTBR:EZBG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 61.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
37.8%per year
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.53x
Belgium Market PEG Ratio Median Figure of 46 Publicly-Listed Companies 1.13x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Eckert & Ziegler BEBIG, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Eckert & Ziegler BEBIG's assets?
Raw Data
ENXTBR:EZBG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €20.02
ENXTBR:EZBG Share Price * ENXTBR (2019-02-18) in EUR €16.3
Europe Medical Equipment Industry PB Ratio Median Figure of 136 Publicly-Listed Medical Equipment Companies 3.05x
Belgium Market PB Ratio Median Figure of 119 Publicly-Listed Companies 1.51x
ENXTBR:EZBG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:EZBG Share Price ÷ Book Value per Share (both in EUR)

= 16.3 ÷ 20.02

0.81x

* Primary Listing of Eckert & Ziegler BEBIG.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Eckert & Ziegler BEBIG is good value based on assets compared to the Europe Medical Equipment industry average.
X
Value checks
We assess Eckert & Ziegler BEBIG's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Eckert & Ziegler BEBIG has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EZBG Future Performance

 How is Eckert & Ziegler BEBIG expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Eckert & Ziegler BEBIG, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Eckert & Ziegler BEBIG expected to grow at an attractive rate?
  • Eckert & Ziegler BEBIG's earnings growth is expected to exceed the low risk savings rate of 0.8%.
Growth vs Market Checks
  • Eckert & Ziegler BEBIG's earnings growth is expected to exceed the Belgium market average.
  • Unable to compare Eckert & Ziegler BEBIG's revenue growth to the Belgium market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTBR:EZBG Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTBR:EZBG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 37.8%
Europe Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.4%
Europe Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Belgium Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Belgium Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTBR:EZBG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTBR:EZBG Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 28 5 1
2018-03-31 27 5 1
2017-12-31 26 5 1
2017-09-30 25 2
2017-06-30 25 6 2
2017-03-31 25 4 1
2016-12-31 25 1 1
2016-09-30 27 -1
2016-06-30 28 -3 -2
2016-03-31 30 -1 -3
2015-12-31 31 1 -4
2015-09-30 30 2 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Eckert & Ziegler BEBIG's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Eckert & Ziegler BEBIG is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTBR:EZBG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Eckert & Ziegler BEBIG Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:EZBG Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 0.27
2018-03-31 0.42
2017-12-31 0.57
2017-09-30 0.74
2017-06-30 0.91
2017-03-31 0.61
2016-12-31 0.27
2016-09-30 -0.26
2016-06-30 -0.89
2016-03-31 -1.60
2015-12-31 -2.31
2015-09-30 -2.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Eckert & Ziegler BEBIG will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Eckert & Ziegler BEBIG's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Eckert & Ziegler BEBIG has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EZBG Past Performance

  How has Eckert & Ziegler BEBIG performed over the past 5 years?

  • Eckert & Ziegler BEBIG's last earnings update was 210 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Eckert & Ziegler BEBIG's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Eckert & Ziegler BEBIG's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Eckert & Ziegler BEBIG's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Eckert & Ziegler BEBIG's 1-year earnings growth is negative, it can't be compared to the Europe Medical Equipment industry average.
Earnings and Revenue History
Eckert & Ziegler BEBIG's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Eckert & Ziegler BEBIG Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTBR:EZBG Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 27.86 0.62 10.61
2018-03-31 26.88 0.98 10.12
2017-12-31 25.89 1.33 9.62
2017-09-30 25.50 1.74 9.38
2017-06-30 25.10 2.15 9.13
2017-03-31 24.99 1.35 9.82
2016-12-31 24.88 0.55 10.51
2016-09-30 26.65 -0.50 12.01
2016-06-30 28.41 -1.56 13.52
2016-03-31 29.75 -2.81 14.22
2015-12-31 31.09 -4.05 14.93
2015-09-30 30.38 -4.40 14.56
2015-06-30 29.67 -4.74 14.20
2015-03-31 29.70 -3.67 14.36 -0.49
2014-12-31 28.82 -3.05 14.21
2014-09-30 30.22 0.46 15.12 -1.39
2014-06-30 29.71 1.84 14.66 -0.98
2014-03-31 28.88 2.12 13.87 2.17
2013-12-31 27.84 3.46 12.91
2013-09-30 28.94 3.96 12.33 1.93
2013-06-30 29.86 4.14 12.19 1.98
2013-03-31 30.08 4.42 12.30 1.93
2012-12-31 31.78 3.87 12.77 2.05
2012-09-30 32.60 1.33 12.84 2.06
2012-06-30 31.28 1.16 12.82 2.21
2012-03-31 30.87 1.28 12.99 1.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Eckert & Ziegler BEBIG has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Eckert & Ziegler BEBIG used its assets less efficiently than the Europe Medical Equipment industry average last year based on Return on Assets.
  • Eckert & Ziegler BEBIG has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Eckert & Ziegler BEBIG's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Eckert & Ziegler BEBIG has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EZBG Health

 How is Eckert & Ziegler BEBIG's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Eckert & Ziegler BEBIG's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Eckert & Ziegler BEBIG is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Eckert & Ziegler BEBIG's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Eckert & Ziegler BEBIG's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 17.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Eckert & Ziegler BEBIG Company Filings, last reported 7 months ago.

ENXTBR:EZBG Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 46.65 0.92 3.35
2018-03-31 46.65 0.92 3.35
2017-12-31 45.66 1.39 5.75
2017-09-30 45.66 1.39 5.75
2017-06-30 46.17 2.32 3.38
2017-03-31 46.17 2.32 3.38
2016-12-31 44.42 5.92 6.30
2016-09-30 44.42 5.92 6.30
2016-06-30 43.57 6.87 3.49
2016-03-31 43.57 6.87 3.49
2015-12-31 38.72 7.86 2.44
2015-09-30 38.72 7.86 2.44
2015-06-30 40.31 8.89 2.29
2015-03-31 40.31 8.89 2.29
2014-12-31 43.22 8.87 2.36
2014-09-30 43.22 8.87 2.36
2014-06-30 45.33 9.29 1.20
2014-03-31 45.64 9.69 2.86
2013-12-31 46.40 10.15 3.60
2013-09-30 43.91 8.07 6.87
2013-06-30 43.54 3.59 1.42
2013-03-31 43.56 4.10 2.25
2012-12-31 42.93 4.62 3.34
2012-09-30 39.96 5.35 3.53
2012-06-30 39.46 5.88 4.80
2012-03-31 39.16 6.41 2.05
  • Eckert & Ziegler BEBIG's level of debt (2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (8.3% vs 2% today).
  • Debt is well covered by operating cash flow (591.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 8.9x coverage).
X
Financial health checks
We assess Eckert & Ziegler BEBIG's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Eckert & Ziegler BEBIG has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EZBG Dividends

 What is Eckert & Ziegler BEBIG's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Eckert & Ziegler BEBIG dividends.
If you bought €2,000 of Eckert & Ziegler BEBIG shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Eckert & Ziegler BEBIG's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Eckert & Ziegler BEBIG's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTBR:EZBG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.6%
Belgium Market Average Dividend Yield Market Cap Weighted Average of 77 Stocks 3.4%
Belgium Minimum Threshold Dividend Yield 10th Percentile 1.3%
Belgium Bottom 25% Dividend Yield 25th Percentile 2.1%
Belgium Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Eckert & Ziegler BEBIG has not reported any payouts.
  • Unable to verify if Eckert & Ziegler BEBIG's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Eckert & Ziegler BEBIG's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Eckert & Ziegler BEBIG has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Eckert & Ziegler BEBIG's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Eckert & Ziegler BEBIG afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Eckert & Ziegler BEBIG has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EZBG Management

 What is the CEO of Eckert & Ziegler BEBIG's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Eckert & Ziegler BEBIG has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Eckert & Ziegler BEBIG's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Eckert & Ziegler BEBIG has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EZBG News

Simply Wall St News

How Eckert & Ziegler BEBIG SA (EBR:EZBG) Can Impact Your Portfolio Volatility

Generally, an investor should consider two types of risk that impact the market value of EZBG. … The other type of risk, which cannot be diversified away, is market risk. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

Does Eckert & Ziegler BEBIG SA's (EBR:EZBG) 140.33% Earnings Growth Make It An Outperformer?

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Investors may find my commentary, albeit very high-level and brief, on Eckert & Ziegler BEBIG SA (EBR:EZBG) useful as an attempt to give more color around how Eckert & Ziegler BEBIG is currently performing. … Check out our latest analysis for Eckert & Ziegler BEBIG?

Simply Wall St -

Should You Have Eckert & Ziegler BEBIG SA.'s (EBR:EZBG) In Your Portfolio?

View our latest analysis for Eckert & Ziegler BEBIG An interpretation of EZBG's beta Eckert & Ziegler BEBIG's beta of 0.98 indicates that the stock value will be less variable compared to the whole stock market. … Based on this beta value, EZBG appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … How EZBG's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Does Eckert & Ziegler BEBIG SA.'s (EBR:EZBG) PE Ratio Warrant A Buy?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for EZBG Price per share = €8.85 Earnings per share = €0.57 ∴ Price-Earnings Ratio = €8.85 ÷ €0.57 = 15.5x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … EZBG’s P/E of 15.5x is lower than its industry peers (34.8x), which implies that each dollar of EZBG’s earnings is being undervalued by investors. … For example, if you are inadvertently comparing lower risk firms with EZBG, then EZBG’s P/E would naturally be lower than its peers, since investors would value those with lower risk with a higher price.

Simply Wall St -

Will Eckert & Ziegler BEBIG SA. (EBR:EZBG) Continue To Underperform Its Industry?

Eckert & Ziegler BEBIG SA.’s (ENXTBR:EZBG) most recent return on equity was a substandard 2.91% relative to its industry performance of 10.92% over the past year. … See our latest analysis for Eckert & Ziegler BEBIG Breaking down Return on Equity Return on Equity (ROE) weighs Eckert & Ziegler BEBIG’s profit against the level of its shareholders’ equity. … Eckert & Ziegler BEBIG’s cost of equity is 8.19%.

Simply Wall St -

How Does Eckert & Ziegler BEBIG SA.'s (EBR:EZBG) Earnings Growth Stack Up Against Industry Performance?

Investors with a long-term horizong may find it valuable to assess Eckert & Ziegler BEBIG SA.'s (ENXTBR:EZBG) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. … For Eckert & Ziegler BEBIG, its latest trailing-twelve-month earnings is €1.33M, which, against last year’s figure, has risen by over 100%. … Given that these values may be relatively nearsighted, I have computed an annualized five-year value for Eckert & Ziegler BEBIG's net income, which stands at €649.11K This means generally, Eckert & Ziegler BEBIG has been able to steadily raise its bottom line over the past few years as well.

Simply Wall St -

How Financially Strong Is Eckert & Ziegler BEBIG SA. (EBR:EZBG)?

On top of this, EZBG has produced cash from operations of €1.36M over the same time period, leading to an operating cash to total debt ratio of 23.06%, signalling that EZBG’s current level of operating cash is high enough to cover debt. … With a debt-to-equity ratio of 5.02%, EZBG's debt level is relatively low. … Next Steps: Although EZBG’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

EZBG Company Info

Map
Description

Eckert & Ziegler BEBIG S.A., through its subsidiaries, develops, manufactures, and sells radiation equipment and related products based on isotope technology. It offers IsoSeed for the treatment of prostate cancer; Mick TP/TPV Applicator System, a brachytherapy implantation technique that allows for seed placement adjustments during implant to adapt changes of prostate size and position; IsoCord, a seed chain that provides radiation protection; IsoStrand, a seed chain that consists of 10 IsoSeeds with 1.0 cm center-to-center spacing for protection against radiation; and needles for LDR brachytherapy. The company also offers IsoSeed I25.S17plus loose seeds for brain tumor treatment; SagiNova and MultiSource HDR (high dose rate) afterloader systems for the HDR brachytherapy applications; SagiPlan software for HDR treatment plans; and Cobalt-60 for various HDR brachytherapy treatments. In addition, it offers gynecological and rectal HDR applicators and accessories; CT/MR contour prostate template sets; tongue and mouth, and nasopharynx applicator sets; breast bridge sets; esophagus applicator and bronchus intraluminal sets; Harrison-Anderson-Mick applicators; and Valencia applicator sets. Further, the company provides products for the temporary brachytherapy of eye cancers, including Ru-106 eye applicators for the treatment of uveal melanoma and retinoblastoma; and I-125 ophthalmic seeds for use in COMS eye applicators to treat eye tumors, such as uveal melanomas and retinoblastomas, as well as offers radiotherapy accessories. It markets and sells its products to oncologists, radiologists, urologists, and medical physicists through a network of distributors and agents worldwide. The company was formerly known as International Brachytherapy s.a. and changed its name to Eckert & Ziegler BEBIG S.A. in June 2011. The company was founded in 1996 and is headquartered in Seneffe, Belgium. Eckert & Ziegler BEBIG S.A. is a subsidiary of Eckert & Ziegler AG.

Details
Name: Eckert & Ziegler BEBIG S.A.
EZBG
Exchange: ENXTBR
Founded: 1996
€38,019,750
2,332,500
Website: http://www.bebig.com
Address: Eckert & Ziegler BEBIG S.A.
Rue Jules Bordet,
Zone Industrielle C,
Seneffe,
Hainaut, 7180,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR EZBG IBT Shares Euronext Brussels BE EUR 15. Dec 1997
BST IBYN IBT Shares Boerse-Stuttgart DE EUR 15. Dec 1997
LSE 0RK0 IBT Shares London Stock Exchange GB EUR 15. Dec 1997
BATS-CHIXE EZBGB IBT Shares BATS 'Chi-X Europe' GB EUR 15. Dec 1997
Number of employees
Current staff
Staff numbers
145
Eckert & Ziegler BEBIG employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/26 20:35
End of day share price update: 2019/02/18 00:00
Last earnings filing: 2018/07/31
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.